The CAMPYLOBACTER QUIK CHEK™ test is a rapid membrane enzyme-linked immunosorbent assay for the qualitative detection of a Campylobacter-specific antigen in human fecal specimens. The CAMPYLOBACTER QUIK CHEK™ test is designed to detect C. jejuni and C. coli from patients with signs and symptoms of gastroenteritis. The test is intended for use with preserved fecal specimens in transport media and unpreserved fecal specimens. Test results should be considered in conjunction with clinical findings and patient history.

Device Description

The CAMPYLOBACTER QUIK CHEK™ test uses antibodies that recognize a Campylobacter-specific antigen in human fecal samples. The device contains a Reaction Window with two vertical lines of immobilized antibodies. The test line ("T") contains antibodies against a Campylobacter-specific antigen. The control line ("C"), contains anti-IgG antibodies. The Conjugate consists of antibodies to a Campylobacter-specific antigen coupled to horseradish peroxidase. To perform the test, a fecal specimen is added to a tube containing a mixture of Diluent and Conjugate. The diluted sample-conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, the Campylobacter-specific antigens in the sample bind to the antibody-peroxidase conjugate. The antigen-antibody complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-Campylobacter antibodies in the line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After a 10-minute incubation, the "T" reaction is examined visually for the appearance of a vertical blue line. A blue line indicates a positive "C" reaction, indicated by a vertical blue line, monitors/confirms that the sample and reagents were added correctly, the reagents were active at the time of performing the assay, and that the sample migrated properly through the Membrane Device. It also confirms the reactivity of the other reagents associated with the assay and that the results are valid.

AI/ML Overview

The document describes the performance of the CAMPYLOBACTER QUIK CHEK™ test, a rapid membrane enzyme-linked immunosorbent assay for the qualitative detection of a Campylobacter-specific antigen in human fecal specimens.

Here's a breakdown of the requested information:

1. Table of Acceptance Criteria and Reported Device Performance

The acceptance criteria for this device are implied by the reported performance relative to a "gold standard" (culture followed by further confirmation for discrepant results). While explicit numerical acceptance criteria are not stated for sensitivity and specificity in the provided text, the reported performance is presented as the device meeting the equivalency with the predicate and performing as well or better than standard culture.

Metric	Acceptance Criteria (Implied by equivalence and performance "as well or better than culture")	Reported Device Performance (CAMPYLOBACTER QUIK CHEK™ test vs. Culture)
Sensitivity	High (to ensure few false negatives)	97.1% (95% CI: 85.5% - 99.9%)
Specificity	High (to ensure few false positives)	99.1% (95% CI: 98.5% - 99.5%)

Additional performance aspects that were evaluated include:

Analytical Sensitivity (LoD): Established at various CFU/mL and CFU/test for C. jejuni and C. coli in raw fecal samples and different transport media.
Analytical Specificity (Cross-Reactivity): No interference found with a broad panel of common intestinal organisms and viruses.
Inclusivity: Found to be reactive with several tested strains of C. coli and C. jejuni (including C. jejuni sub-species doylei).
Reproducibility: 100% correlation in results across different labs, technicians, and kit lots, with expected results 100% of the time.
Prozone Effect: No prozone effect observed at high antigen concentrations.

2. Sample Size Used for the Test Set and Data Provenance

Sample Size (Prospective Study): 1552 patients.
Data Provenance (Prospective Study): The study was conducted at 4 independent sites. The country of origin is not explicitly stated, but the submission is to the U.S. FDA, and U.S. formulation information is mentioned for interfering substances, implying a U.S. context. The study was prospective, as it involved "Prospective incoming fecal specimens collected and tested."
Sample Size (Retrospective Study): 30 specimens.
Data Provenance (Retrospective Study): The data provenance (country) for the retrospective specimens is not specified. The study was retrospective.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

The ground truth for the primary clinical performance comparison (prospective study) was established by culture. While culture is a standard method, the text does not mention the number or qualifications of experts involved in performing or interpreting the initial culture results.

For the discrepant specimens (14 from the prospective study and 30 from the retrospective study), further characterization was performed using:

An FDA-cleared commercial Microassay well EIA
An FDA-cleared commercial molecular test
In-house PCR (detecting the 16s rRNA gene of Campylobacter specific identification, and species-specific identification for the retrospective study)
Bidirectional sequencing

The number of experts involved in interpreting these additional confirmatory tests or establishing a final consensus ground truth for discrepants is not specified in the document, nor are their qualifications.

4. Adjudication Method for the Test Set

For the initial 1552 prospective specimens, the comparison was directly between the CAMPYLOBACTER QUIK CHEK™ test and culture.

For the 14 discrepant specimens (culture negative/device positive, or culture positive/device negative) from the prospective study, an adjudication method was used by referring them for additional testing with multiple methods (commercial EIA, commercial molecular test, in-house PCR, bidirectional sequencing) at TECHLAB. The results of these additional tests were used to "confirm" the status of the discrepant samples. For example, 9 out of 13 culture negative/device positive samples were confirmed positive by all additional test methods. This suggests a form of consensus or comprehensive secondary testing was used to re-evaluate the true status of these discrepant cases. The specific consensus rule (e.g., majority vote, all methods agree) is not explicitly detailed.

For the 30 retrospective specimens, all were initially Campylobacter spp. culture positive and were "further characterized as Campylobacter spp. positive by an FDA-cleared commercial Microassay well EIA, an FDA-cleared commercial molecular test, in-house PCR... and bidirectional sequencing." This indicates a multi-method confirmation process for the ground truth of these samples before being tested retrospectively by the device.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was Done, and Effect Size

No, an MRMC comparative effectiveness study involving human readers with and without AI assistance was not done. This device is an in vitro diagnostic (IVD) assay for antigen detection, not an AI-powered image analysis or diagnostic aid for human readers. Therefore, the concept of human readers improving with AI assistance is not applicable here.

6. If a Standalone Study Was Done

Yes, a standalone study was performed ("algorithm only without human-in-the-loop performance"). The entire performance evaluation, including the prospective and retrospective studies, analytical sensitivity, specificity, inclusivity, and prozone, evaluates the performance of the CAMPYLOBACTER QUIK CHEK™ test device itself. The primary clinical performance (sensitivity and specificity) is presented for the device's ability to detect the target antigen compared to culture.

7. The Type of Ground Truth Used

The primary ground truth used for the clinical performance evaluation (prospective study) was bacterial culture.

For discrepant samples, the ground truth was further refined and confirmed by multiple orthogonal laboratory methods, including an FDA-cleared commercial Microassay well EIA, an FDA-cleared commercial molecular test, in-house PCR, and bidirectional sequencing. This can be considered a form of expert consensus derived from multiple confirmatory tests.

8. The Sample Size for the Training Set

The document does not provide information on a training set sample size. This is likely because the CAMPYLOBACTER QUIK CHEK™ test is a traditional immunoassay device, not an AI/machine learning model that typically requires a large training dataset. The studies described are for validation and performance evaluation of the manufactured device.

9. How the Ground Truth for the Training Set Was Established

As no training set is mentioned for an AI/machine learning model, this question is not applicable.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and then the word "ADMINISTRATION" in a smaller font size below that.

January 22, 2018

Techlab, Inc. Donna Link Director Regulatory and Compliance 2001 Kraft Drive Blacksburg, Virginia 24060

Re: K173217

Trade/Device Name: Campylobacter Quik Chek Regulation Number: 21 CFR 866.3110 Regulation Name: Campylobacter fetus serological reagents Regulatory Class: Class I Product Code: LQP Dated: September 29, 2017 Received: October 25, 2017

Dear Donna Link:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

{1}------------------------------------------------

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Ribhi Shawar -S For

Uwe Scherf, M.Sc., Ph.D. Director Division of Microbiology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K173217

Device Name CAMPYLOBACTER QUIK CHEK

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
☒ Prescription Use (Part 21 CFR 801 Subpart D)	☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

CAMPYLOBACTER QUIK CHEK™ 510(k) SUMMARY

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92.

Applicant/Contact Information:

Date Prepared:	January 22, 2018
Name:	TECHLAB, Inc.
Address:	2001 Kraft DriveCorporate Research CenterBlacksburg, VA 24060 USA

Contact Person:	Donna T. Link
Phone Number:	540-953-1664
Email:	dlink@techlab.com

1.1 Manufacturing Facility Address

TECHLAB, Inc. 20 Corporate Drive Radford, VA 24141 USA

1.2 Product and Trade Name of the Device

CAMPYLOBACTER QUIK CHEK™

1.3 Common Name or Classification Name

Campylobacter spp. detection test

1.4 Classification and Regulation

Class I 21 CFR 866.3110: Campylobacter fetus serological reagents

1.5 Product Code

LQP - Campylobacter spp.

1.6 Panel

83 Microbiology

1.7 Reason for Premarket Notification

The development of a new rapid membrane enzyme immunoassay for the qualitative detection of Campylobacter spp. in a single use cassette.

{4}------------------------------------------------

Intended Use

Explanation

Worldwide, Campylobacter species are the most common cause of bacterial gastroenteritis, with 400-500 million cases of diarrhea each vear. Infants in developing countries are at even greater risk. as are travelers to those countries. Campylobacter-associated gastroenteritis is estimated to affect nearly 1 million people a year in the USA. In approximately 1 of 1000 cases, Campylobacter jejuni is closely linked to the subsequent development of Guillian-Barre Syndrome, an acute auto-immune paralysis. C. jeiuni infection has also been associated with reactive arthritis in both children and adults. When individuals with severe symptoms of gastroenteritis seek medical help, the clinician is faced with multiple possible causes that can present with similar clinical features (e.g., diarrhea, nausea, vomiting, fever, abdominal pain) but that require very different, often conflicting, types of treatment.

For Campylobacter, the current standard for identification is bacterial culture followed by microscopic examination of the organisms. Although this traditional method is straightforward, it has two major limitations. First, pathogenic species of Campylobacter are microaerophilic or strictly anaerobic, so that exposure of culture or feces to environmental oxygen leads to death or inactivation of the bacteria. Thus, during transport or storage of specimens under aerobic conditions, the number of viable organisms can decrease, leading to potentially inaccurate culture results. Second. Campylobacter species are slow-growing, requiring from 48-72 hours before reaching a point where the culture can safely be reported as negative. Such delays can leave the clinician in a quandary and the patient with non-specific, ineffective, or even inappropriate treatment.

The CAMPYLOBACTER QUIK CHEK™ test allows detection of Campylobacter jejuni and Campylobacter coli, the species most commonly associated with human disease, in less than 30 minutes. Furthermore, the CAMPYLOBACTER QUIK CHEK™ test does not rely on bacterial viability, and can be performed on the bench-top with samples that have been exposed to air.

Device Description

The CAMPYLOBACTER QUIK CHEK™ test uses antibodies that recognize a Campylobacterspecific antigen in human fecal samples. The device contains a Reaction Window with two vertical lines of immobilized antibodies. The test line ("T") contains antibodies against a Campylobacterspecific antigen. The control line ("C"), contains anti-IgG antibodies. The Conjugate consists of antibodies to a Campylobacter-specific antigen coupled to horseradish peroxidase. To perform the test, a fecal specimen is added to a tube containing a mixture of Diluent and Conjugate. The diluted sample-conjugate mixture is added to the Sample Well and the device is allowed to incubate at room temperature for 15 minutes. During the incubation, the Campylobacter-specific antigens in the sample bind to the antibody-peroxidase conjugate. The antigen-antibody complexes migrate through a filter pad to a membrane where they are captured by the immobilized anti-Campylobacter antibodies in the line. The Reaction Window is subsequently washed with Wash Buffer, followed by the addition of Substrate. After a 10-minute incubation, the "T" reaction is examined visually for the appearance of a vertical blue line. A blue line indicates a positive "C" reaction, indicated by a vertical blue line, monitors/confirms that the sample and reagents were added correctly, the reagents were active at the time of performing the assay, and that the sample migrated properly through the

{5}------------------------------------------------

Membrane Device. It also confirms the reactivity of the other reagents associated with the assay and that the results are valid.

Materials Provided

Membrane Devices 25, each pouch contains 1 device ●
Conjugate (2.5 mL) Antibody to a Campylobacter-specific antigen coupled to horseradish ● peroxidase in a buffered protein solution
Diluent (22 mL) Buffered protein solution with graduated dropper assembly ●
. Positive Control (2 mL) - Campylobacter-specific antigen in a buffered protein solution
Wash Buffer (12 mL) Buffered solution with graduated dropper assembly .
Substrate (3.5 mL) Solution containing tetramethylbenzidine ●
. Disposable plastic transfer pipettes - graduated at 25 µL, 100 µL, 200 µL, 300 µL, 400 µL and 500 µL

The predicate device (ImmunoCard STAT!® CAMPY) and the CAMPYLOBACTER QUIK CHEK™ test both detect Campylobacter spp. (C. jejuni and C. col) in fecal specimens and are substantially equivalent in principle. The following table shows a comparison of both devices.

Similarities
Item	DeviceK173217	PredicateK090700
Indications for use	The CAMPYLOBACTER QUIK CHEK™test is a rapid membrane enzyme-linkedimmunosorbent assay for the qualitativedetection of a Campylobacter-specificantigen in human fecal specimens. TheCAMPYLOBACTER QUIK CHEK test isdesigned to detect C. jejuni and C. colifrom patients with symptoms ofgastroenteritis. The test is intended foruse with unpreserved human fecalspecimens and fecal specimens that arein transport media. Test results shouldbe considered in conjunction with clinicalfindings and patient history.	ImmunoCard STAT! CAMPY is animmunochromatographic rapid test forthe qualitative detection of specificCampylobacter antigens in humanstool. ImmunoCard STAT! CAMPYdetects C. jejuni and C. coli in humanstool, where stool may be eitherunpreserved or preserved in Cary-Blair-based transport media. Testresults are to be used in conjunctionwith information available from thepatient clinical evaluation and otherdiagnostic procedures.
Measured analyte	Detection of Campylobacter-specificantigens (C. jejuni and C. coli)	Detection of Campylobacter-specificantigens (C. jejuni and C. coli)
Type of Test	Qualitative	Same
Controls	Positive and negative control included inthe kit Internal "C" Control line	Same
Format	Single Use Membrane Cassette	Same
TargetPopulation	Persons suspected of havingCampylobacter infection	Same
Storage	Refrigerated (2°C – 8°C)	Same

{6}------------------------------------------------

There are no differences between the subject device and the predicate(s) with respect to indications and intended use.

Differences
Item	DeviceK173217	PredicateK090700
Specimen Type	Fecal specimens in Cary-Blair andC&S Transport Media	Fecal specimens in Cary-Blair Transport Media
Time to Result	<30 minutes	< 25 minutes
Antibody Format	Monoclonal/Polyclonal	Monoclonal/Monoclonal

Summary of Performance Data

Prospective Study

The performance of the CAMPYLOBACTER QUIK CHEK™ test was evaluated at 4 independent sites. Prospective incoming fecal specimens were collected and tested by culture and the CAMPYLOBACTER QUIK CHEK™ test. The following table shows a summary of the clinical performance of the CAMPYLOBACTER QUIK CHEK™ test for all 4 sites combined. The results of the study show that the CAMPYLOBACTER QUIK CHEK™ test exhibited a sensitivity of 97.1%, and a specificity of 99.1% with culture.

Age and Gender Distribution

Age information was available for 1552 patients. The ages ranged from less than 1 year to 100 years. Of the 1552 patients, 15.7% were ≤ 18 years. The gender identification was 38.7% females and 61.3% males. No difference in test performance was observed based on patient age or gender.

CAMPYLOBACTER QUIK CHEK™ test versus Culture

N = 1552	Culture Positive	Culture Negative
CAMPYLOBACTER QUIK CHEK™Positive	34	13*
CAMPYLOBACTER QUIK CHEK™Negative	1**	1504

		95% Confidence Limits
Sensitivity	97.1%	85.5% - 99.9%
Specificity	99.1%	98.5% - 99.5%

The 14 discrepant specimens were further characterized by additional testing at TECHLAB. This testing included an FDA-cleared commercial Microassay well EIA, an FDA-cleared commercial molecular test, inhouse PCR (detecting the 16s rRNA gene of Campylobacter specific identification), and bidirectional sequencing.

Nine of the 13 specimens that were culture negative and CAMPYLOBACTER QUIK CHEK™ test positive were confirmed to be positive for C. jejuni with all test methods.

Two of the 13 specimens that were culture negative and CAMPYLOBACTER QUIK CHEK™ test positive were confirmed to be positive with the commercial EIA, in-house PCR, and bidirectional sequencing.

{7}------------------------------------------------

One of the 13 specimens that was culture negative and CAMPYLOBACTER QUIK CHEK™ test positive was confirmed to be positive with an FDA-cleared commercial molecular test, in-house PCR and bidirectional sequencing.

One specimen that was culture negative and CAMPYLOBACTER QUIK CHEK™ test positive was confirmed to be positive for C. upsaliensis (an important pathogen) by species-specific PCR and sequencina.

** The one specimen that was culture positive and CAMPYLOBACTER QUIK CHEK™ test negative was confirmed to be negative for C. jejuni or C. coli with all test methods.

Retrospective Study

Supplemental testing was performed on 30 retrospective specimens. The patient ages ranged from less than 11 months to 74 years. All retrospective specimens were Campylobacter spp. culture positive and were further characterized as Campylobacter spp. positive by an FDA-cleared commercial Microassay well EIA, an FDA-cleared commercial molecular test, in-house PCR (detecting the 16s rRNA gene of Campylobacter spp., and species-specific identification), and bidirectional sequencing. These specimens were then tested in the CAMPYLOBACTER QUIK CHEK™ test. All 30 specimens tested positive for Campylobacter spp. by all methods, yielding 100% correlation with all test methods.

Reproducibility

The reproducibility of the CAMPYLOBACTER QUIK CHEK™ test was determined using 8 fecal specimens that were coded to prevent their identification during testing. Testing was performed at 2 independent laboratories and on-site at TECHLAB, Inc. The samples included 2 negative samples, 2 high negative samples, 2 low positive samples and 2 moderate positive samples. The samples were tested in triplicate twice a day over a 5-day period by multiple technicians at each site using 2 different kit lots. A positive and negative control was run with each panel of the masked samples. The results from each laboratory were submitted to TECHLAB, Inc. and compared with in-house results. The results were consistent among the different locations, and exhibited a correlation of 100%. The samples produced the expected results 100% of the time.

Analytical Sensitivity

The analytical sensitivity of the test was determined by using C. jejuni and C. coli whole organism culture preparations in a sample matrix. The concentration of C. jejuni and C. coli organisms in fecal matrix at which specimens are positive by the CAMPYLOBACTER QUIK CHEK™ test 95% of the time is the assay Limit of Detection (LoD).

The Limit of Detection (LoD) for the CAMPYLOBACTER QUIK CHEK™ test with raw fecal samples was established at 8.39 x 104 CFU/mL (1271 CFU/test) for C. jejuni. For specimens in Protocol™ Cary Blair media, the LoD was established at 1.78 x 108 CFU/mL (2781 CFU/test) for C. jejuni. For specimens in Protocol™ C&S media, the LoD was established at 7.25 x 104 CFU/mL (1133 CFU/test) for C. jejuni.

The Limit of Detection (LoD) for the CAMPYLOBACTER QUIK CHEK™ test with raw fecal samples was established at 7.70 x 108 CFU/mL (11667 CFU/test) for C. coli. For specimens in Protocol™ Cary Blair media, the LoD was established at 2.22 x 10° CFU/mL (34688 CFU/test) for C. coli. For specimens in Protocol™ C&S media, the LoD was established at 1.56 x 10° CFU/mL (24375 CFU/test) for C. coli.

{8}------------------------------------------------

Analytical Specificity (Cross Reactivity)

The CAMPYLOBACTER QUIK CHEK™ test was evaluated for cross-reactivity with common intestinal organisms and viruses listed below. None of the organisms or viruses were shown to interfere with the performance of the CAMPYLOBACTER QUIK CHEK™ test.

Acinetobacter baumannii	Aeromonas hydrophila	Bacillus cereus
Bacillus subtilis	Bacteroides fragilis	Campylobacter concisus
Campylobacter fetus	Candida albicans	Citrobacter freundii
Clostridium bifermentans	Clostridium difficile	Clostridium perfringens
Edwardsiella tarda	Enterobacter cloacae	Enterococcus faecalis
Escherichia coli	Escherichia coli EIEC	Escherichia coli EPEC
Escherichia coli ETEC	Escherichia coli O157:H7 (non-toxigenic)	Escherichia hermanii
Escherichia coli O157:H7 (toxigenic)	Escherichia fergusonii	Lactobacillus acidophilus
Helicobacter pylori	Klebsiella pneumoniae	Peptostreptococcus anaerobius
Lactococcus lactis	Listeria monocytogenes	Prevotella melaninogenica
Plesiomonas shigelloides	Porphyromonas asaccharolytica	Pseudomonas fluorescens
Proteus vulgaris	Pseudomonas aeruginosa	Shigella dysenteriae
Salmonella enterica typhimurium	Serratia marcescens	Staphylococcus aureus
Shigella flexneri	Shigella sonnei	Staphylococcus epidermidis
Staphylococcus aureus (Cowan's)	Streptococcus agalactiae	Coxsackievirus B2, B3, B4, B5
Vibrio parahaemolyticus	Yersinia enterocolitica	Norovirus
Adenovirus Type 1, 2, 3, 5, 40, 41	Human Coronavirus
Echovirus 9, 11, 18, 22, 33Human Rotavirus	Enterovirus 68, 69, 70, 71

Campylobacter species that were shown to be reactive with the CAMPYLOBACTER QUIK CHEK™ test.

C. helveticus (strain 54661) was found to be positive at 3.08 x 10° CFU/mL (4 x LoD of C. coli)

C. lari (strain 23947) was found to be positive at 3.08 x 10° CFU/mL (4 x LoD of C. coll)

C. upsaliensis (strain 14913) was found to be positive at 1.54 x 10° CFU/mL (2 x LoD of C. col)

Inclusivity Study

The specificity of the CAMPYLOBACTER QUIK CHEK™ test was evaluated using several strains of Campylobacter jejuni and Campylobacter coli. All strains listed generated positive results when tested.

C. coli strains: 11283, 10956, 17755, 36994, 53138

C. jejuni sub-species jejuni strains: 11284, 6951, 12081, 29411, 38106
C. jejuni sub-species doylei strain: 24567

Interfering Substances (U.S. Formulation)

The following substances had no effect on positive or negative CAMPYLOBACTER QUIK CHEK™ test results analyzed at the concentrations indicated:

Barium sulfate (5% w/v), Benzalkonium Chloride (1% w/v), Ciprofloxacin (0.25% w/v), Ethanol (1% w/v), Hog gastric mucin (3.5% w/v), Human blood (40% v/v), Hydrocortisone (1% w/v), Imodium® (5% v/v), Kaopectate® (5% v/v), Leukocytes (0.05% w/v), Maalox® Advanced (5% v/v), Mesalazine (10% w/v), Metronidazole (0.25% w/v), Mineral Oil (10% w/v), Mylanta® (4.2 mg/mL), Naproxen Sodium (5% w/v). Nonoxynol-9 (40% w/v). Nystatin (1% w/v). Palmitic Acid/Fecal Fat (40% w/v). Pepto-Bismol® (5% v/v), Phenylephrine (1% w/v), Polyethylene glycol 3350 (10% w/v ), Prilosec OTC® (5 µg/mL), Sennosides (1% w/v), Simethicone (10% w/v), Steric Acid/Fecal Fat (40% w/v), Tagamet® (5 ug/mL), TUMS® (50 µg/mL), Human Urine (5% v/v), and Vancomvcin (0,25% w/v),

{9}------------------------------------------------

Prozone

To ensure that a high concentration of Campylobacter antigen does not interfere with a positive reaction in the CAMPYLOBACTER QUIK CHEK™ test, high positive samples were prepared by spiking a negative fecal pool at a concentration possibly observed in clinical specimens. A total of 5 different dilutions of C. jejuni and C. coli whole organism culture preparation, up to and including the clinically observed high concentration, were prepared and tested in triplicate. The results demonstrated that there was no overall prozone effect, that elevated levels of antigen did not affect the detection of the antigen.

CONCLUSION

The conclusions drawn from the nonclinical and clinical tests demonstrate that the CAMPYLOBACTER QUIK CHEK™ test is as safe and as effective and performs as well or better than standard culture, and is equivalent to the predicate device in performance. The information submitted in this premarket notification is complete and supports a substantial equivalence decision.

Regulation Number and Section

§ 866.3110

Campylobacter fetus serological reagents.(a)
Identification. Campylobacter fetus serological reagents are devices that consist of antisera conjugated with a fluorescent dye used to identifyCampylobacter fetus from clinical specimens or cultured isolates derived from clinical specimens. The identification aids in the diagnosis of diseases caused by this bacterium and provides epidemiological information on these diseases.Campylobacter fetus is a frequent cause of abortion in sheep and cattle and is sometimes responsible for endocarditis (inflammation of certain membranes of the heart) and enteritis (inflammation of the intestines) in humans.(b)
Classification. Class I (general controls).